Globus Medical/$GMED
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Globus Medical
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Ticker
$GMED
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
5,300
ISIN
US3795772082
Website
Globus Medical Metrics
BasicAdvanced
$8B
44.03
$1.34
1.33
-
Price and volume
Market cap
$8B
Beta
1.33
52-week high
$94.93
52-week low
$54.48
Average daily volume
1.4M
Financial strength
Current ratio
4.445
Quick ratio
2.598
Long term debt to equity
2.005
Total debt to equity
2.27
Interest coverage (TTM)
198.65%
Profitability
EBITDA (TTM)
720.812
Gross margin (TTM)
67.05%
Net profit margin (TTM)
7.39%
Operating margin (TTM)
18.16%
Effective tax rate (TTM)
20.34%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
5.90%
Return on equity (TTM)
4.63%
Valuation
Price to earnings (TTM)
44.031
Price to revenue (TTM)
3.188
Price to book
1.95
Price to tangible book (TTM)
4.23
Price to free cash flow (TTM)
15.464
Free cash flow yield (TTM)
6.47%
Free cash flow per share (TTM)
380.37%
Growth
Revenue change (TTM)
32.26%
Earnings per share change (TTM)
145.70%
3-year revenue growth (CAGR)
37.72%
10-year revenue growth (CAGR)
17.97%
3-year earnings per share growth (CAGR)
-0.87%
10-year earnings per share growth (CAGR)
2.84%
What the Analysts think about Globus Medical
Analyst ratings (Buy, Hold, Sell) for Globus Medical stock.
Bulls say / Bears say
Globus Medical's merger with NuVasive has significantly expanded its product portfolio and global reach, positioning the company as a formidable competitor in the musculoskeletal solutions market. (globenewswire.com)
The company reported a 60.6% increase in worldwide net sales for 2024, reaching $2.519 billion, indicating strong market demand and successful integration of acquired assets. (globenewswire.com)
Globus Medical's continued investment in enabling technologies, such as the ExcelsiusGPS robotic system, positions it at the forefront of surgical innovation, potentially driving future growth. (globenewswire.com)
The company received an FDA warning letter regarding its ExcelsiusGPS robotic system, citing deficiencies in complaint handling and reporting, which could impact product reputation and sales. (panabee.com)
Cost of sales increased to 41% of net sales in 2024, up from 35% the previous year, due to merger-related inventory amortization and elevated product expenses, potentially squeezing gross margins. (panabee.com)
Globus Medical faces near-term financial challenges with $450 million in convertible senior notes due in March 2025, coupled with negative other income of $45 million from foreign currency losses and increased interest expenses. (panabee.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Globus Medical Financial Performance
Revenues and expenses
Globus Medical Earnings Performance
Company profitability
Globus Medical News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
GlobeNewsWire·1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Accesswire·2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Globus Medical stock?
Globus Medical (GMED) has a market cap of $8B as of June 28, 2025.
What is the P/E ratio for Globus Medical stock?
The price to earnings (P/E) ratio for Globus Medical (GMED) stock is 44.03 as of June 28, 2025.
Does Globus Medical stock pay dividends?
No, Globus Medical (GMED) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Globus Medical dividend payment date?
Globus Medical (GMED) stock does not pay dividends to its shareholders.
What is the beta indicator for Globus Medical?
Globus Medical (GMED) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.